文献速递创伤与烧伤重症综合管理与镇静镇痛

创伤性脑损伤中的生物流体标志物:一项系统范围综述

Biofluid Biomarkers in Traumatic Brain Injury: A Systematic Scoping Review.
PubMed 文献 · Neurocrit Care · 2021-01-05

细胞因子、凝血试验和神经组织蛋白研究最多,S100 beta最常见(220篇,21.2%)。皮质醇是唯一在血液、脑脊液、尿液和唾液中均检测的标志物,最常见采样时间为入院时和伤后24小时内。结论是生物流体标志物有诊断和预后潜力,但无单一确定性标志物,分类框架可为设计多标志物组合面板提供指导。

要点

  • S100 beta是最常见标志物,在21.2%(220篇)研究中检测。
  • 细胞因子(560项)、凝血试验(515项)、神经组织蛋白(502项)研究最多。
  • 皮质醇是唯一在血液、脑脊液、尿液和唾液中均检测的标志物。
  • 研究主要聚焦血液和中枢神经系统来源标志物、成人、重型和钝性损伤,最常见采样时间为入院时和伤后24小时内。

适用人群与场景

  • 纳入研究主要聚焦成人人群、重型和钝性创伤性脑损伤。

诊断标准与关键阈值

  • 原文未提及

处置流程与药物剂量

  • 原文未提及

红旗征与不能漏的情况

  • 原文未提及

研究设计与关键结果

  • 系统范围综述,检索截至2019年1月,从25354条记录中纳入1036项原始人体研究。
  • 细胞因子、凝血试验和神经组织蛋白分别在560、515和502项研究中评估。
  • S100 beta为最常见标志物,在21.2%(220篇)研究中检测。
  • 皮质醇是唯一在血液、脑脊液、尿液和唾液中均检测的标志物。
  • 最常见采样时间为入院时和伤后24小时内。
  • 最常见结局指标为标志物浓度变化、格拉斯哥昏迷量表、格拉斯哥结局量表、脑CT和死亡率。

证据类型、等级与局限

  • 证据类型:系统范围综述。
  • 局限:原文未系统评价偏倚风险;研究主要聚焦成人、重型及钝性损伤,限制外推。

对床旁实践的改变

  • 原文结论为生物流体标志物有诊断和预后潜力,但无单一确定性标志物,不能单独用于床旁决策。
  • 分类框架可指导设计多标志物组合面板,但需进一步研究验证。

指南或共识出处

  • 原文未提及

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

Emerging evidence suggests that biofluid-based biomarkers have diagnostic and prognostic potential in traumatic brain injuries (TBI). However, owing to the lack of a conceptual framework or comprehensive review, it is difficult to visualize the breadth of materials that might be available. We conducted a systematic scoping review to map and categorize the evidence regarding biofluid-based biochemical markers of TBI. A comprehensive search was undertaken in January 2019. Of 25,354 records identified through the literature search, 1036 original human studies were included. Five hundred forty biofluid biomarkers were extracted from included studies and classified into 19 distinct categories. Three categories of biomarkers including cytokines, coagulation tests, and nerve tissue proteins were investigated more than others and assessed in almost half of the studies (560, 515, and 502 from 1036 studies, respectively). S100 beta as the most common biomarker for TBI was tested in 21.2% of studies (220 articles). Cortisol was the only biomarker measured in blood, cerebrospinal fluid, urine, and saliva. The most common sampling time was at admission and within 24 h of injury. The included studies focused mainly on biomarkers from blood and central nervous system sources, the adult population, and severe and blunt injuries. The most common outcome measures used in studies were changes in biomarker concentration level, Glasgow coma scale, Glasgow outcome scale, brain computed tomography scan, and mortality rate. Biofluid biomarkers could be clinically helpful in the diagnosis and prognosis of TBI. However, there was no single definitive biomarker with accurate characteristics. The present categorization would be a road map to investigate the biomarkers of the brain injury cascade separately and detect the most representative biomarker of each category. Also, this comprehensive categorization could provide a guiding framework to design combined panels of multiple biomarkers.

来源:Neurocrit Care,查看原文。版权归原作者所有。

参考来源

  1. Edalatfar M, Piri SM, Mehrabinejad MM, et al. Biofluid Biomarkers in Traumatic Brain Injury: A Systematic Scoping Review. Neurocrit Care. 2021. PMID: 33403583. doi:10.1007/s12028-020-01173-1

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。